about
Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico studyWhy CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisEmerging concepts and approaches for chemokine-receptor drug discovery.Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3The emerging role of CXC chemokines and their receptors in cancer.G protein-coupled receptors--recent advancesCCR6 as a possible therapeutic target in psoriasis.Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain developmentChemokines, neuronal-glial interactions, and central processing of neuropathic pain.Chemokines and chemokine receptors: new insights into cancer-related inflammation.Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.Targeting chemokine receptors in allergic disease.4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation.A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.Mechanisms regulating chemokine receptor activity.Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?Therapeutic potential of chemokine receptor antagonists for liver disease.The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.Targeting chemokines in proteinuria-induced renal disease.Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists.Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.Designing small molecule CXCR3 antagonists.Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain.Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations.In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies.Peripheral monocyte expression of the chemokine receptors CCR2, CCR5 and CXCR3 is altered at parturition in healthy women and in women with systemic lupus erythematosus.Analysis of patents on anti-allergic therapies issued in China from 1988 to 2008.Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.Evidence on the identity of the CXCR2 antagonist AZD-5069.Mechanical stretch upregulates SDF-1α in skin tissue and induces migration of circulating bone marrow-derived stem cells into the expanded skin.Multistep continuous-flow synthesis in medicinal chemistry: discovery and preliminary structure-activity relationships of CCR8 ligands.Are we just learning the scales on the chemokine receptor pianos?Chemokine levels in serum of children with atopic dermatitis with regard to severity and sensitization status.
P2860
Q28481687-ED1CA272-E2D8-4BA7-B29E-97600A5F1949Q28742993-A1D9C3B7-9D1C-4EC6-AB12-1DE5C6252E3DQ33763369-ED3FF504-8150-4952-A097-1E22B666030DQ34012132-6EB8F16E-C11E-4E11-A3DD-015EDC0CB51BQ34263645-F59F1CD4-8877-4517-A1BC-2F4D3AF74118Q35065927-2725AAE6-A7F9-45F6-8271-149ED57A07CCQ36980670-746906F1-4BB8-499C-ABD9-49A24FBEFF42Q37115195-21965D31-3343-4CEE-9CAE-9EC6F0A3E0A8Q37684327-DE36A8C9-CEEE-464A-AFB0-5633C9D7D92DQ37694068-204A617C-C374-414D-A245-2EDC1196454FQ37723178-F7B218F9-B620-43D9-B93A-958B18B25D69Q37790697-9D2E1701-0FEE-4B63-A75C-75865A04249FQ37827167-B3A8EF8D-A903-4FA1-9C39-1DDE31010E97Q37832529-68B9B79F-233A-4866-AD7C-4E85D7387027Q37873497-D76D6323-30CD-4A90-82C6-786872AF47E3Q37936463-C033C973-7BCA-45FD-AF15-7881135576B7Q37942973-19BF77BA-59D6-4A36-AFAD-73BD4D30BED7Q37944472-B94ACC2D-1840-441F-975F-188361413164Q37960533-2B535C21-4873-475C-8638-3F1128A7BD78Q37989141-A52EDCD1-DFA0-468E-A5D7-7BBD3CB89146Q38026076-5BBE5F83-1AD4-40B2-A9FA-1BB1E4B72F61Q38074216-4DCE6D6A-EF17-42A8-9543-38B569F68CA9Q38083321-D689F83E-E81B-473E-BD6B-B17C31152536Q38583607-82ED97D4-B712-4AA9-A6BA-95237759BA33Q38834435-DE4B4183-D1FF-4E05-B60E-A603259A21F6Q39051765-0253B56B-AE4A-4EA2-92A1-58A936D6AEAEQ39227824-C983ECC7-3B81-4C66-938F-3C2FB3C5A32BQ41037672-E04AE343-FA45-44F2-B12A-8D7E9232DDBBQ41533540-24B3F5FA-EED3-4C1E-AFED-C9E092A603ECQ41728362-849D6718-FCBB-4598-BC80-7843B09D49BFQ42518908-6B0ECE91-9754-4B85-819E-613150679449Q43061739-3703B166-2B58-4F0A-99F3-45FC01756AD3Q45999111-EF26F3A1-CBAC-4EB8-A904-A71CD9D1A0F1Q46394676-2C928029-1451-4108-AF82-C95FFDDF8524Q50850394-56C13613-C6BE-4132-BA7C-A4AC09093C77Q50953857-33591936-803C-4E44-A89F-B93C2E5CB684Q51601857-0E9020AF-84E8-479F-A98A-3E60874E06C1Q51618907-7A65EC8D-7709-46D2-88EA-2909A71A6993
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemokine receptor antagonists: part 2.
@en
Chemokine receptor antagonists: part 2.
@nl
type
label
Chemokine receptor antagonists: part 2.
@en
Chemokine receptor antagonists: part 2.
@nl
prefLabel
Chemokine receptor antagonists: part 2.
@en
Chemokine receptor antagonists: part 2.
@nl
P2860
P1476
Chemokine receptor antagonists: part 2.
@en
P2093
James E Pease
Richard Horuk
P2860
P304
P356
10.1517/13543770802641353
P407
P577
2009-02-01T00:00:00Z